key: cord-1012312-pgmab3hr authors: Keswani, M.; Mehta, N.; Mazer-Amirshahi, M.; Tran, Q.K.; Pourmand, A. title: Sedation in mechanically ventilated covid-19 patients: A narrative review for emergency medicine providers date: 2021-05-14 journal: Am J Emerg Med DOI: 10.1016/j.ajem.2021.05.030 sha: 107e9f556c772b9ded674e9b9ea6cc5201619a74 doc_id: 1012312 cord_uid: pgmab3hr nan Sedatives play an integral role in patients with COVID-19 by acting as induction agents prior to neuromuscular blockade and reducing discomfort during periods of mechanical ventilation. During induction, sedatives facilitate amnesia and cause a blunted sympathetic response, creating favorable intubation conditions 1 . Post-intubation maintenance sedation improves pulmonary compliance, prevents asynchrony, and facilitates adaption to the ventilator; however, in severe cases, additional paralytics are required 2, 3 . Although emergency medicine physicians are typically involved in the initial stabilization of patients that require prolonged sedation and mechanical ventilation, limited ICU capacity has created longer boarding times for patients in the ED. As such, ED physicians require a basic understanding regarding management of sedation for these critically ill patients, which will be summarized in this review. Etomidate is a sedative hypnotic frequently used as an induction agent during rapid sequence intubation (RSI). It has a rapid onset and short duration of action, making it a suitable for unstable patients 4 . Of note, elevations in arterial carbon dioxide are associated with etomidate and can exacerbate hypercarbia and acidosis in COVID-19 patients 4 . Etomidate is associated with reduced plasma cortisol levels that persist for hours after administration; however the significance of this finding is controversial 4 . Although data have been largely extrapolated from non-COVID patients, etomidate is a useful agent in COVID-19 patients due to its ability to maintain hemodynamic stability, short duration of action, and favorable adverse effect profile. 5 (Table 1) . Ketamine is a dissociative anesthetic that is used as an induction agent for RSI, procedural sedation, and analgesia. Due to its ability to elevate blood pressure and heart rate by inhibiting the reuptake of endogenous catecholamines, ketamine is recommended for induction in COVID-19 patients that are hemodynamically unstable 6 . Increased secretions are a wellknown adverse effect of ketamine due to preservation of normal pharyngeal and laryngeal reflexes; however, the use of an anti-sialagogue such as atropine can reduce secretions which may reduce aerosolizing the virus 7 . Previous studies found a reduction in the release of inflammatory markers such as IL-6 after the administration of ketamine, which could be useful in stifling the cytokine storm that leads to rapid deterioration in COVID-19 patients 8 . Furthermore, ketamine does not cause significant respiratory depression, which can facilitate weaning COVID-19 patients from mechanical ventilation 9 . While ketamine has been associated J o u r n a l P r e -p r o o f with hallucinations and psychological disturbances, there is low concern for these effects in COVID-19 patients due to the deep level of sedation required for mechanical ventilation. More recent studies are examining the role of ketamine in treating neuropsychiatric conditions in COVID-19 patients due to its dual function as an NMDA receptor antagonist and immune modulator 10 . Ketamine's ability to maintain hemodynamic stability make it an attractive option for sedation. Propofol is a sedative hypnotic used for induction and maintenance of sedation in mechanically ventilated patients. It is a popular choice for sedation due to its highly predictable pharmacokinetic properties, including rapid onset and short duration of action 11 . The adverse effect profile of propofol makes it suboptimal for sedating critically ill COVID-19 patients. Diminished cardiac output and hypotension are known adverse effects of propofol and these effects are exacerbated in the setting of mechanical ventilation 11 . The use of propofol as an induction or maintenance agent in COVID-19 patients with shock could lead to profound hypotension. Propofol infusion syndrome is a rare, but potentially fatal adverse effect that can occur in the setting of prolonged use. It is characterized by bradycardia, metabolic acidosis, and rhabdomyolysis. Propofol should be discontinued, and sedation changed to another agent(s), such as dexmetatomadine and midazolam, and supportive care for complications initiated 12 . It has been suggested the critical illness myopathy COVID-19 patients experience could be due in part to low-grade myotoxicity associated with prolonged propofol administration 13 . Although limited data exists on the use of propofol in COVID-19 patients, its adverse effect profile limits its use for prolonged sedation. Dexmedetomidine, a presynaptic α 2 adrenergic agonist, can be used for light sedation or in conjunction with other sedatives if deeper sedation is required for effective mechanical ventilation 14 . Prolonged use of dexmedetomidine in the ICU setting has been studied extensively and it has been shown to reduce sepsis-related lung injury and ischemia-reperfusion injury in the heart, kidney, and brain 15 . The most common adverse effects include hypotension and bradycardia within a few hours of initiation and the drug is contraindicated in patients with bradydysrhythmias 16 . It is hypothesized that the use of dexmedetomidine as part of the sedation strategy in COVID-19 patients may improve oxygenation by reducing hypoxic pulmonary vasoconstriction and ventilation-perfusion mismatch 17 . Furthermore, dexmedetomidine has been shown to modulate several immune pathways that may be advantageous to COVID-19 patients 17 . The results of these studies will be instrumental in providing definitive data regarding the use of dexmedetomidine; however, in the interim clinicians can continue to use this drug to maintain sedation in mechanically ventilated patients. Benzodiazepines are sedative hypnotics that are most commonly used for continuous sedation in the setting of anxiety and agitation in the ICU 18 . Although they are efficacious, there are several studies that indicate worse outcomes with the use of benzodiazepines compared to non-benzodiazepine sedatives in ventilated patients who require longer periods of sedation 19, 20 . These include longer time spent on the ventilator, risk of hemodynamic instability due to decreased respiratory drive and hypotension, as well as an increased risk for delirium 19, 20 . A recent study comparing the use of dexmedetomidine and midazolam in 35 patients with severe COVID-19 requiring non-invasive ventilation, found greater effectiveness and fewer adverse events in the patients sedated using dexmedetomidine 21 . The adverse events in the benzodiazepine group were related to excess sedation resulting in aspiration or intubation and intubation due to refractory hypoxemia 21 . Still, benzodiazepines may be a viable option if the preferred sedatives are contraindicated or in patients that develop propofol-related infusion syndrome 22 . They may also be beneficial for the treatment of acute agitation and as an adjunctive therapy to maintain deep sedation in mechanically ventilated patients with COVID-19. Of note, some benzodiazepines such as lorazepam, have large amounts of propylene glycol diluent, which causes metabolic acidosis; therefore, midazolam is the preferred choice for prolonged or repeated use. Inhalational volatile anesthetics such as isoflurane have many beneficial properties that would make them promising for maintenance sedation; however, their use for this purpose is still experimental and the extensive technology and training that is required to deliver these drugs may be a significant limiting factor. On behalf of the NEAR Investigators. Does the Sedative Agent Facilitate Emergency Rapid Sequence Intubation? Sedation for critically ill patients with COVID-19: Which specificities? One size does not fit all Delivering evidence-based critical care for mechanically ventilated patients with COVID-19 StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020. Accessed Reemergence of TIVA in COVID times Consensus guidelines for managing the airway in patients with COVID-19: Guidelines Ketamine use in the COVID-19 era: be cautious! Consider Adjunctive Ketamine in Mechanically Ventilated Coronavirus Disease-2019 Patients StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020. Accessed Ketamine in COVID-19 patients: Thinking out of the box StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020. Accessed Does prolonged propofol sedation of mechanically ventilated COVID-19 patients contribute to critical illness myopathy? Analgesia and Sedation Strategies in Mechanically Ventilated Adults with COVID-19 The effect of dexmedetomidine and clonidine on the inflammatory response in critical illness: a systematic review of animal and human studies Sedation, Analgesia, and Paralysis in COVID-19 Patients in the Setting of Drug Shortages Dexmedetomidine: another arrow in the quiver to fight COVID-19 in intensive care units Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit A randomized trial of intermittent lorazepam versus propofol with daily interruption in mechanically ventilated patients Dexmedetomidine vs Midazolam for Sedation of Critically Ill Patients: A Randomized Trial A comparative study on clinical effects of dexmedetomidine and midazolam on patients with severe coronavirus disease 2019 on noninvasive ventilation Dexmedetomidine and worsening hypoxemia in the setting of COVID-19: A case report The Landscape of Prescription Drug Shortages During the COVID-19 Pandemic